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Abstract
Background: To overcome the limitations regarding two dimensional (2D) greyscale (GS) transrectal ultrasound (TRUS)-
guided biopsy in prostate cancer (PCa) detection and tissue packaging in biopsy processing, there is an ongoing focus on
new imaging and pathology techniques. A three-dimensional (3D) model of the prostate with biopsy needle guidance
can be generate by the Navigo™ workstation (UC-care, Israel). The SmartBX™ system (UC-care, Israel) provides a prostate
biopsy core preembedding method. The aim of this study was to compare cancer detection rates between the 3D TRUS-
guidance and preembedding method with conventional 2D GS TRUS-guidance among patients undergoing prostate
biopsies.
Methods: We retrospectively analyzed the records of all patients who underwent prostate biopsies for PCa detection at
our institution from 2007 to 2016. The cohort was divided into a 2D GS TRUS-guidance cohort (from 2007 to
2013, n = 1149) and a 3D GS TRUS-guidance with preembedding cohort (from 2013 to 2016, n = 469). Effect
of 3D GS TRUS-guidance with preembedding on detection rate of PCa and clinically significant PCa (Gleason
score ≥ 7 or > 2 biopsy cores with a Gleason score 6) was compared to 2D GS TRUS-guidance using
regression models.
Results: Detection rate of PCa and clinically significant PCa was 39.0 and 24.9% in the 3D GS TRUS cohort
compared to 33.5 and 19.0% in the 2D GS TRUS cohort, respectively. On multivariate regression analysis the
use of 3D GS TRUS-guidance with preembedding was associated with a significant increase in detection rate
of PCa (aOR = 1.33; 95% CI: 1.03–1.72) and clinically significant PCa (aOR = 1.47; 95% CI: 1.09–1.98).
Conclusion: Our results suggest that 3D GS TRUS-guidance with biopsy core preembedding improves PCa
and clinically significant PCa detection compared to 2D GS TRUS-guidance. Additional studies are needed to
justify the application of these systems in clinical practice.
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Background
Prostate cancer (PCa) is the most common malignancy
among Western males [1]. Early detection of PCa reduces
PCa-related mortality and reduces the risk of being diag-
nosed and developing advanced or metastatic disease [2].
PCa detection with systematic prostate biopsies under
ultrasound guidance, in men identified with elevated
serum prostate-specific antigen (PSA) and / or abnormal
digital rectal examination (DRE), is considered as the
preferred diagnostic method by guidelines from leading
organizations [3, 4]. Although standard two dimensional
(2D) greyscale (GS) transrectal ultrasound (TRUS)--
guided biopsy is able to detect PCa, it has well known
limitations. 2D GS TRUS has low sensitivity and specifi-
city for detection of PCa and is therefore used to guide
prostate biopsies rather than used as a diagnostic modal-
ity. Even in TRUS-guided biopsy there is still a 20–30%
risk of sampling error with underdiagnosis of PCa that
requires definitive treatment as a result [5, 6]. There is
also poor correlation with final pathology [7–9]. Unfor-
tunately, imaging is not the only part with influence on
PCa detection as inadequate tissue packaging in biopsy pro-
cessing also tends to reduce PCa detection outcomes [10].
To overcome these limitations and improve PCa de-
tection, there is an ongoing focus on new imaging and
pathology techniques.
3D GS TRUS is an imaging method that allows simul-
taneous imaging of the prostate in axial and sagittal
plane, followed by a computer reconstructed third cor-
onal plane as well as a 3D image [5]. Effectiveness of 3D
GS TRUS in detection and local staging of PCa is con-
troversial as limited studies reported different outcomes
[5, 11–13]. However, the feasibility of 3D TRUS in assist-
ing biopsy needle guidance was recognised in phantom
and patient studies [14–16]. More recently, Peltier et al.
reported significant higher detection rates of clinically
significant PCa using a 3D TRUS-guided biopsy system
in clinical practice [17].
Biopsy processing with preembedding methods of
prostate biopsy cores result in optimal tissue presenta-
tion with preservation of shape and avoidance of arte-
facts and deformation, and have shown to improve
histologic yield [18, 19]. Moreover, Rogatsch et al. dem-
onstrated that the improvement of histologic yield using
an optimized preembedding method led to a higher fre-
quency of PCa diagnosis [20].
Based on these findings, prostate biopsy sessions in
our institution are performed since September 2013 with
a phantom validated 3D GS TRUS-guided biopsy system
(Navigo™ workstation, UC-care Medical Systems Israel)
and a semi-automated prostate biopsy core preembed-
ding method proven to improve histologic yield (the
SmartBX™ system, UC-care Medical Systems Israel) [15,
21]. The purpose of the present study was to investigate
the value of 3D GS TRUS-guidance and biopsy core pre-
embedding in the detection of (clinically significant) PCa
compared to conventional 2D GS TRUS-guidance in a
consecutive cohort of men undergoing systematic pros-
tate biopsies due to a clinical suspicion of PCa.
Methods
In this retrospective cohort study, all consecutive men
who underwent prostate biopsies between January 2007
and January 2016 in the Urology Department at the Jeroen
Bosch Hospital in ‘s Hertogenbosch, the Netherlands,
were included. Patient files were consulted for relevant in-
formation. Prostate biopsy sessions performed in patients
with no prior history of PCa and a serum PSA level
between 4.0 and 10.0 μg/L or PSA < 4.0 μg/L and a suspi-
cious DRE were included in the study. We divided the eli-
gible prostate biopsy sessions into two cohorts. From
January 2007 up to September 2013 consecutive biopsy
sessions were performed in the 2D TRUS cohort. The 3D
TRUS cohort consisted of the consecutive biopsy sessions
with preembedding from September 2013 up to January
2016.
2D TRUS cohort protocol
All prostate biopsy sessions were performed with
prophylactic antibiotics in the lateral decubitus pos-
ition. The prostate gland was assessed and scanned and
prostate volume measurements were done using the el-
lipsoid formula, using a BK medical ultrasound ma-
chine (type 2202) and BK medical sidefire probe (type
8808, 6–10MHz). A 12-core biopsy protocol, under
periprostatic local anaesthesia, was then performed
consisting of biopsies on both sides in the peripheral
zone, 2 biopsies of each base, mid and apex. The biopsy
was performed using a spring-loaded gun with
18-gauge needles (Bard Magnum biopsy gun). Biopsy
cores were placed in two vials, each vial containing 6
cores of one prostate lobe. Prostate cores were proc-
essed and examined in the hospital pathology labora-
tory. Number of cores per vial, length of biopsy cores,
number of positive biopsy cores, ISUP 2005 Gleason
score and tumour volume% of biopsy cores (since
2012) were reported.
3D TRUS cohort protocol
The 3D GS TRUS protocol is basically similar to the
2D TRUS protocol. The 3D GS TRUS system
(Navigo™ workstation) was incorporated side by side
in the room with 2D ultrasound images transferred
and displayed on the 3D TRUS screen. A 3D model
of the prostate was built after prostate volume mea-
surements and planimetry was done. The outline of
the prostate border was manually traced and recorded
on a slice-by-slice basis. In real time using an
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electromagnetic system (Fig. 1), the 12-core biopsy
protocol was performed with tracking, displaying and
recording of biopsy needle trajectory locations. Previ-
ously marked regions of interest were shown with
colour indications on screen and sampled. Biopsy
cores were fixed separately on six different cassettes
(two cores of apex, mid and base on both sides) using
the Smart-Bx device (Additional file 2). SmartBx™ de-
vice is a semi-automated prostate biopsy core preem-
bedding method, with a designed membrane to which
the cores stay attached throughout pathology lab pro-
cessing, and placed in two formalin-filled vials (3 cas-
settes in each vial with two cores of apex, mid and
base of one prostate lobe).
In both cohorts, biopsy sessions were performed by
different operators. Operator was recorded for analysis
and split into experienced (> 100 procedures/year and >
10 years of experience using TRUS guided biopsies) and
less experienced (< 100 procedures/year). The following
primary outcomes were compared: detection rate of PCa
and detection rate of clinically significant (Gleason
score ≥ 7 or Gleason score 6 with at least 3 positive bi-
opsy cores). The following secondary outcomes were
compared in patients with PCa at biopsy: amount of
positive biopsy cores; ratio positive biopsy cores per total
biopsy cores; tumour volume% of biopsy cores and Glea-
son score.
Statistical
Statistical analyses were performed using SPSS Statistics
23.0®. Descriptive statistics were used to summarize base-
line characteristics. Continuous variables were presented
with means and standard deviations (SD) or median and
interquartile ranges (IQR) based on symmetrical distribu-
tion with the independent two sample t-test or
Mann-Whitney U test used to assess differences, respect-
ively. Percentage scores were presented for categorical vari-
ables with differences assessed using the Pearson
Chi-Square test. To determine association between (clinic-
ally significant) PCa and the 3D GS TRUS-guided system
with preembedding we calculated the crude and adjusted
odds ratio with their 95% confidence intervals (CI) for each
outcome compared to the 2D GS TRUS cohort using uni-
variate and multivariate logistic regression analyses. Covari-
ables were entered on multivariate analysis, selected based
on literature and/or performance: inclusion in the adjusted
model when addition of the variable resulted in at least
10% change in the regression coefficient. A P < 0.05 was
considered statistically significant in all analyses [3, 22–24].
Results
Between January 2007 and January 2016 we performed
2917 prostate biopsy sessions in 2171 different patients
(Fig. 2). 2D TRUS biopsies were performed from 2007 to
2013 and 3D TRUS biopsies were performed from 2013
Fig. 1 Navigo™ 3D model with biopsy locations
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to 2016. A total of 1618 prostate biopsy sessions in 1339
different patients met inclusion criteria. 469 (29.0%) and
1149 (71.0%) biopsy sessions were performed in the 3D
TRUS and 2D TRUS cohort respectively. Patients with
missing data on clinical, biopsy and pathology variables
(PSA n = 4, DRE n = 112, prostate volume n = 13, length
of cores n = 20) were excluded for multivariate analyses.
Additionally, information on primary outcome was inad-
equate for 45 biopsy sessions and therefore these ses-
sions were revised by one uropathologist.
Patient and biopsy characteristics
Several characteristics differed among the two cohorts for
whole group and subgroups (biopsy naive and prior nega-
tive biopsy sessions only) analyses (Table 1). For whole
group analysis, prostate biopsy sessions in the 3D TRUS
cohort were more likely done in older patients (mean age
in years; 64.6 vs. 63.0, p < 0.001), in patients with larger
prostate volumes (median volume in cc; 46 vs. 40, p
< 0.001), in a biopsy naive setting (80.0% vs. 75.1%,
p < 0.05) and by the experienced operator (73.6% vs.
43.3%, p < 0.001) compared to the 2D TRUS cohort. The
amount of biopsy cores taken per session was comparable
in both cohorts (mean cores 12.3 vs. 12.3, p = 0.555), while
fragmentation of biopsy cores occurred significantly less
often in the 3D TRUS cohort (37.7% vs. 1.9%, p < 0.001).
The length of biopsy cores in millimetres was significantly
larger in the 3D TRUS cohort (mean length in mm; 16.08
vs. 12.38, p < 0.001).
Detection rate
In the 3D TRUS cohort, a total of 183 out of 469
(39.0%) and 117 out of 469 (24.9%) were found positive
for PCa and clinically significant PCa compared to 335
out of 1149 (33.5%) and 218 out of 1149 (19.0%) in the
2D TRUS cohort, respectively (Table 2). On univariate
analysis the 3D TRUS cohort was significantly associated
with detection of PCa (OR = 1.27, 95% CI 1.02–1.59)
and clinically significant PCa (OR 1.42, 95% CI 1.10–
1.83). On multivariate regression analysis with age, DRE,
Fig. 2 Study population
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Table 1 Patient and biopsy characteristics
Total 2D TRUS 3D TRUS P value
Whole group (1339 patients)
Number of biopsy sessions N = 1618 N = 1149 (71.0%) N = 469 (29.0%)
Age in years, mean (SD) 63.4 (SD: 6.30) 63.0 (SD: 6.27) 64.6 (SD: 6.24) < 0.001
PSA in ng/mL, mean (SD) 6.92 (SD: 1.84) 6.95 (SD: 1.85) 6.84 (SD: 1.84) 0.248
DRE:
• benign, n (%) 1028 (68.3%) 739 (69.3%) 289 (65.7%) 0.167
• suspicious, n (%) 478 (31.7%) 327 (30.7%) 151 (34.3%)
Prostate volume in ml, median (IQR) 41 (30–56) 40 (30–54) 46 (33–63) < 0.001
Type of biopsy sessions:
• Biopsy naive, n (%) 1238 (76.5%) 863 (75.1%) 375 (80.0%) 0.037
• Prior negative, n (%) 380 (23.5%) 286 (24.9%) 94 (20.0%)
Type of operator:
• Experienced, n (%) 843 (52.1%) 498 (43.3%) 345 (73.6%) < 0.001
• Less experienced, n (%) 775 (47.9%) 651 (56.7%) 124 (26.4%)
Biopsy cores per session, mean (SD) 12.3 (SD 1.04) 12.3 (SD 1.05) 12.3 (SD 1.02) 0.555
Biopsy sessions with fragmentation, n (%) 442 (27.3%) 433 (37.7%) 9 (1.9%) < 0.001
Length of biopsy cores in mm, mean (SD)a 13.84 (SD: 2.98) 12.38 (SD: 2.82) 16.08 (SD: 1.41) < 0.001
Biopsy naïve group (1238 patients)
Number of biopsy sessions N = 1238 N = 863 (69.7%) N = 375 (30.3%)
Age in years, mean (SD) 63.5 (SD: 6.46) 63.0 (SD: 6.43) 64.7 (SD: 6.35) < 0.001
PSA in ng/mL, mean (SD) 6.73 (SD: 1.87) 6.72 (SD: 1.87) 6.74 (SD: 1.86) 0.877
DRE:
• benign, n (%) 777 (66.9%) 556 (68.6%) 221 (63.0%) 0.063
• suspicious, n (%) 385 (33.1%) 255 (31.4%) 130 (37.0%)
Prostate volume in ml, median (IQR) 40 (30–55) 40 (29–52) 44 (32–60) < 0.001
Type of operator:
• Experienced, n (%) 643 (51.9%) 368 (42.6%) 275 (73.3%) < 0.001
• Less experienced, n (%) 595 (48.1%) 495 (57.4%) 100 (26.7%)
Biopsy cores per session, mean (SD) 12.2 (SD 0.79) 12.2 (SD 0.80) 12.2 (SD 0.77) 0.779
Biopsy sessions with fragmentation, n (%) 334 (27.0%) 325 (37.7%) 9 (2.4%) < 0.001
Length of biopsy cores in mm, mean (SD)a 13.84 (SD: 2.96) 12.33 (SD: 2.78) 16.07 (SD: 1.40) < 0.001
Prior negative group (321 patients)
Number of biopsy sessions N = 380 N = 286 (75.3%) N = 94 (24.7%)
Prior negative sessions specified:
• Second session 300 (78.9%) 225 (78.7%) 75 (79.8%) 0.658
• Third session 64 (16.8%) 47 (16.4%) 17 (18.1%)
• Fourth session 14 (3.7%) 12 (4.2%) 2 (2.1%)
• Fifth session 2 (0.5%) 2 (0.7%) 0
Age in years, mean (SD) 63.1 (SD: 5.79) 62.8 (SD: 5.80) 63.9 (SD: 5.73) 0.135
PSA in ng/mL, mean (SD) 7.54 (SD: 1.60) 7.65 (SD: 1.54) 7.20 (SD: 1.73) 0.023
DRE:
• benign, n (%) 251 (73.0%) 183 (71.8%) 68 (76.4%) 0.396
• suspicious, n (%) 93 (27.0%) 72 (28.2%) 21 (23.6%)
Prostate volume in ml, median (IQR) 46 (32–62) 44 (31–58) 54 (39–70) < 0.001
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prostate volume and type of operator included as covari-
ates, the 3D TRUS cohort remained significantly associ-
ated with detection of PCa (aOR 1.33, 95% CI 1.03–1.72)
and clinically significant PCa (aOR 1.47, 95% CI 1.09–
1.98). The association between 3D TRUS and detection
of (clinically significant) PCa on multivariate regression
analysis for the subgroups demonstrated significance for
clinically significant PCa in the biopsy naive group (aOR
1.41, 95% CI 1.02–1.96) and for PCa in the prior nega-
tive group (aOR 1.78, 95% CI (1.04–3.04) (Table 2).
PCa positive biopsies: biopsy characteristics and Gleason
score
Tumour biopsy characteristics between the 3D GS
TRUS cohort and the 2D GS TRUS cohort in patients
with positive PCa biopsies were not statistically different
as the amount of positive biopsy cores, the ratio positive
biopsy cores out of the total biopsy cores and the per-
centage of tumour volume per PCa biopsy session did
not differ between both groups (Additional file 3). The
biopsy Gleason score among patients with PCa positive
biopsies was significantly different between the 3D
TRUS and 2D TRUS cohort in the whole group and bi-
opsy naive subgroup analyses as more clinically signifi-
cant and Gleason score ≥ 7 PCa was found in the 3D
TRUS cohort (P < 0.05) (Additional file 4).
Discussion
Limited studies with small sample sizes have been per-
formed to assess the value of 3D GS TRUS in guiding
prostate biopsies. Peltier et al. published the first cohort
study into 3D TRUS-guided prostate biopsy and detec-
tion rate of PCa. In 220 consecutive biopsy naive men,
detection rate of PCa was significantly higher in the 3D
TRUS group using the Urostation (Koelis®) compared
with 2D TRUS (50.0% versus 33.6%, p < 0.05) [17]. In
contrary, a previous study carried out in our institution
with 325 men showed no added value of 3D TRUS guid-
ance compared to 2D with all biopsy cores preembedded
(aOR 0.79, 95% CI 0.47–1.34) [25].
This present study, covering a period of 9 full years
with 1618 prostate biopsy sessions, demonstrated higher
detection rates of PCa and clinically significant PCa with
the use of 3D TRUS-guidance and preembedding com-
pared to conventional 2D GS TRUS-guidance. These
findings may be explained by different hypotheses. On
one side, 3D TRUS could have improved detection as it
offers the ability to accurately register the location of the
biopsy needle tract within the gland, possibly leading to
better distribution of biopsy cores; instead needle place-
ment with 2D-guidance is not always homogeneously
distributed and tends to cluster.[15, 26–28] Besides,
length of biopsy cores was significantly larger and frag-
mentation occurred significantly less in the 3D GS
TRUS cohort possibly also aiding detection of PCa as
Iczkowski et al. and Rogatsch et al. demonstrated in
their studies that length of biopsy tissue significantly
correlates with PCa detection rate and higher frequency
of PCa diagnosis was found with an improved preem-
bedding method, respectively [19, 20, 25].
Multiparametric MRI (mpMRI) of the prostate is in-
creasingly used in the diagnostic pathway of PCa and
three large studies, evaluating the detection rates of an
MRI-targeted biopsy approach and TRUS guided sys-
tematic biopsy approach, have recently been performed
in biopsy-naïve men [30–32].
While the PRECISION trial demonstrated that an MRI
targeted biopsy approach detected significantly more
clinically significant PCa in comparison with a TRUS
systematic biopsy approach both the MRI First and 4M
Study demonstrated comparable detection rates of clin-
ically significant PCa between the standard TRUS sys-
tematic biopsy and MRI targeted biopsy approach.
Obtaining an mpMRI before biopsy improves the detec-
tion of clinically significant PCa but at present does not
avoid the need for systematic biopsy as shown in the sys-
tematic review from Moldovan et al. and the MRI FIRST
study where 10 to 15% of clinically significant PCa were
still missed in men with a negative mpMRI [31, 33]. Even
in the Dutch 4M study with high-quality MRI standards,
7% (21/317) of all men with a suspicious mpMRI scan had
clinically significant PCa only on systematic biopsy [32]. A
high-quality TRUS systematic biopsy, possibly with the
use of 3D TRUS-guidance and preembedding, could
therefore still be important in the current diagnostic
setting where mpMRI is also included.
Table 1 Patient and biopsy characteristics (Continued)
Total 2D TRUS 3D TRUS P value
Type of operator:
• Experienced, n (%) 200 (52.6%) 130 (45.5%) 70 (74.5%) < 0.001
• Less experienced, n (%) 180 (47.4%) 156 (54.5%) 24 (25.5%)
Biopsy cores per session, mean (SD) 12.6 (SD 1.56) 12.7 (SD 1.53) 12.6 (SD 1.67) 0.519
Biopsy sessions with fragmentation, n (%) 113 (29.7%) 113 (39.2%) 0 < 0.001
Length of biopsy cores in mm, mean (SD)a 13.81 (SD: 3.05) 12.54 (SD: 2.96) 16.10 (SD: 1.48) < 0.001
aBiopsy sessions with fragmentation were excluded for these analyses
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On the other side, as a retrospective study, our ana-
lysis has important limitations that could have influ-
enced the outcome. First of all, biopsy sessions after
September 2013 were performed with 3D TRUS guid-
ance and the preembedding method; as a consequence,
their independent influence on the detection rate of PCa
cannot be assessed. However as both procedures act on
different aspects of PCa diagnosis, a joint positive effect
was hypothesized over masking of independent results.
Secondly, difference in study time period could have had
an impact on PCa detection rate as different unidentified
factors influencing PCa detection rate could have chan-
ged during these time periods. Prostate biopsy selection
in both cohorts however was not based on important
pre-biopsy tests such as mpMRI and/or novel bio-
markers. Both cohorts differed in baseline characteristics
with older age, lower prostate volume and a biopsy naive
setting all associated with higher odds of PCa and sig-
nificant PCa on univariate and multivariate analysis in
our study (Additional file 1: Table S1). Beside this, we
decided in our study to include the Large Grade Group
1 (GS 3 + 3) as clinically significant PCa. Recent EAU
guidelines use the definition of GG ≥ 2 (GS ≥3 + 4) for
clinical significant PCa. This matches with the newly in-
troduced ISUP scoring system, where no separation is
made between large and small GG 1 (GS 3 + 3) PCa
[29]. We decided to include large GS 3 + 3 = 6 PCa as
clinically significant as this is currently still used as a cri-
teria for active surveillance versus radical treatment in
low-risk PCa patients.
In addition, experience level of operators was various.
Although a correction strategy was implemented, re-
sidual confounding could still be possible. Last, 32.4%
(944/2917) of all our prostate biopsy sessions were ex-
cluded on the basis of PSA inclusion criteria. In line with
the literature we excluded men with high PSA levels as
improved detection of significant PCa cancer is most ne-
cessary in the PSA grayzone from 4 to 10 ng/mL, while
men with higher PSA levels tend to be diagnosed accur-
ately with TRUS-guided systematic biopsies [30–32].
As a result, association between 3D TRUS-guidance
with preembedding and detection of PCa could be par-
tially biased on the basis of confounding and selection.
Despite these limitations in relation to the detection of
PCa, there are other possible clinical applications for our
approach. The 3D TRUS system is not only developed
for direct imaging and navigation, but also for procedure
planning with recording and integration of exact loca-
tions of biopsy cores and updating of pathology results.
With the possibility to assess the exact spatial coordi-
nates of each previous needle trajectory, a ‘biopsy map’
can be built based on (positive) previous core taken and
adequate sample sites can potentially be chosen in prior
negative patients or in patients in active surveillance.
Additionally, in our study biopsy core length and Glea-
son score were significantly higher in the cohort with
3D GS TRUS-guidance and preembedding. As more bi-
opsy core length from a presumably spatial better biop-
sied prostate gland can be pathologically examined,
correlation with prostatectomy specimens could possibly
be improved and thereby prevent men with unfavourable
disease to be placed in active surveillance or less
Table 2 Detection rate of all prostate cancer and clinically
significant prostate cancer
Whole group
Detection rate of PCa
Biopsy cohort: n/N (%) Crude OR (95% CI) aORa (95% CI)
Total 568/1618 (35.1%)
3D TRUS 183/469 (39.0%) 1.27 (1.02–1.59) 1.33 (1.03–1.72)
2D TRUS 385/1149 (33.5%) Reference Reference
Detection rate of clinically significant PCa
n/N (%) Crude OR (95% CI) aORa (95% CI)
Total 335/1618 (20.7%)
3D TRUS 117/469 (24.9%) 1.42 (1.10–1.83) 1.47 (1.09–1.98)
2D TRUS 218/1149 (19.0%) Reference Reference
Biopsy naive group
Detection rate of PCa
n/N (%) Crude OR (95% CI) aORb (95% CI)
Total 466/1238 (37.6%)
3D TRUS 151/375 (40.3%) 1.17 (0.92–1.50) 1.20 (0.90–1.60)
2D TRUS 315/863 (36.5%) Reference Reference
Detection rate of clinically significant PCa
n/N (%) Crude OR (95% CI) aORb (95% CI)
Total 295/1238 (23.8%)
3D TRUS 105/375 (28.0%) 1.38 (1.04–1.82) 1.41 (1.02–1.96)
2D TRUS 190/863 (22.0%) Reference Reference
Prior negative group
Detection rate of PCa
n/N (%) Crude OR (95% CI) aORc (95% CI)
Total 102/380 (26.8%)
3D TRUS 32/94 (34.0%) 1.59 (0.96–2.64) 1.78 (1.04–3.04)
2D TRUS 70/286 (24.5%) Reference Reference
Detection rate of clinically significant PCa
n/N (%) Crude OR (95% CI) aORd (95% CI)
Total 40/380 (10.5%)
3D TRUS 12/94 (12.8%) 1.35 (0.66–2.77) –
2D TRUS 28/286 (9.8%) Reference Reference
aadjusted Odds Ratio: adjusted for age, DRE, prostate volume and
physician (PSA and Type of biopsy session resulted in < 10% change in β)
b adjusted Odds Ratio: adjusted for age, DRE and prostate volume and
physician (PSA resulted in < 10% change in the β)
c adjusted Odds Ratio: adjusted for age and Log (prostate volume), (age,
PSA, DRE and physician resulted in < 10% change in the β)
d the number of events per variable are too low to be analyzed in
multivariable logistic regression analysis
Aa et al. BMC Urology           (2019) 19:23 Page 7 of 9
aggressive treatments. However caution should be exer-
cised for interpretation of Gleason score differences be-
tween both cohorts as Gleason grading of PCa was
updated at the end of 2014 during an ISUP Consensus
Conference [29].
As a consequence, higher Gleason scores in the 3D
TRUS cohort could be partially the result of these new
grading pattern definitions. We will therefore investigate
these potential applications in future prospective studies
and pathology concordance studies. These findings high-
light the need for future research regarding the comple-
mentary value of 3D TRUS guidance and preembedding
in the combination with mpMRI and other new diagnos-
tic applications.
Conclusion
The current study suggests an added value of 3D
TRUS-guidance and preembedding compared to conven-
tional 2D GS TRUS-guidance regarding detection rate of
PCa and clinically significant PCa among patients undergo-
ing prostate biopsies. At the same time, 3D TRUS-guidance
and preembedding provided significant more biopsy core
tissue length and higher biopsy Gleason scores. Additional
prospective studies and studies concerning pathology cor-
relation are needed to justify the routine application of 3D
GS TRUS-guidance and biopsy core preembedding.
Additional files
Additional file 1: Table S1. Univariate and multivariate logistic
regression analyses of individual risk factors for detection of prostate
cancer and clinically significant prostate cancer. (DOCX 14 kb)
Additional file 2: SmartBxTM device prostate biopsy core
preembedding. (PPTX 95 kb)
Additional file 3: Tumour biopsy characteristics among patients with
positive biopsies. (XLSX 12 kb)
Additional file 4: Biopsy Gleason score among patients with positive
biopsies. (XLSX 13 kb)
Abbreviations
2D: Two-dimensional; 3D: Three-dimensional; CI: Confidence interval;
DRE: Digital rectal examination; GS: Greyscale; IQR: Interquartile range;
mpMRI: Multiparametric Magnetic Resonance Imaging; OR: Odds ratio;
PCa: Prostate cancer; PSA: prostate-specific antigen; SD: Standard deviation;
TRUS: Transrectal ultrasound
Acknowledgements
Not applicable.
Funding
No funding.
Availability of data and materials
All data generated or analysed during this study are included in this
published article and its supplementary information files.
Authors‘ contributions
AvdA conceived the idea for the study, made the protocol and wrote the
manuscript with CKM. CKM performed the data collection, conducted the
analyses and wrote the manuscript with AvdA. MG made the protocol and
assisted with the data collection. AvdA, CKM and MG had access to all of the
research data. JvdL revised necessary pathology. JvdL, HB, BS, MM and HW
assisted with protocol development. HB, BS, MS, MM and HW contributed to
the interpretation of the data and critically revised earlier draft versions. All
authors read and approved the final manuscript.
Ethics approval and consent to participate
The ethical committee of the Jeroen Bosch Hospital gave ethical approval
for this study with a non-WMO declaration. Informed consent for the current
study was not required, because the data-collection was retrospective in
design.
Consent for publication
Not applicable.
Competing interests
All authors declares that they have no conflict of interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Urology, Jeroen Bosch Hospital, Post office box 90153,
‘s-Hertogenbosch 5200 ME, The Netherlands. 2Department of Pathology,
Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands. 3Department of
Urology, Radboud University Medical Centre, Nijmegen, The Netherlands.
4Electrical Engineering, Eindhoven University of Technology, Eindhoven, The
Netherlands. 5Department of Urology, AMC University Hospital, Amsterdam,
The Netherlands.
Received: 6 August 2018 Accepted: 31 March 2019
References
1. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al.
Recent trends in incidence of five common cancers in 26 European
countries since 1988: analysis of the European Cancer observatory. Eur J
Cancer. 2015;51(9):1164–87.
2. Schröder FH, Hugosson J, Carlsson S, Tammela TL, Määttänen L, Auvinen A,
et al. Screening for prostate Cancer decreases the risk of developing
metastatic disease: findings from the European randomized study of
screening for prostate Cancer. Eur Urol. 2012;62(5):745–52.
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al.
Screening and prostate cancer mortality: results of the European
randomised study of screening for prostate Cancer (ERSPC) at 13 years of
follow-up. Lancet. 2014;384(9959):2027–35.
4. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al.
American Cancer Society guideline for the early detection of prostate
cancer: update 2010. CA Cancer J Clin. 2010;60(2):70–98.
5. Smeenge M, de la Rosette JJ, Wijkstra H. Current status of transrectal
ultrasound techniques in prostate cancer. Curr Opin Urol. 2012;22(4):
297–302.
6. Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ,
et al. Contemporary role of systematic prostate biopsies: indications,
techniques and implications for patient care. Eur Urol. 2013;63(2):214–30.
7. Wilkinson BA, Hamdy FC. State-of-the-art staging in prostate cancer. BJU Int.
2001;87(5):423–31.
8. Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, et al.
Pathological findings and prostate specific antigen outcomes after
radical prostatectomy in men eligible for active surveillance--does the
risk of misclassification vary according to biopsy criteria? J Urol. 2010;
183(2):539–44.
9. Bul M, Zhu X, Rannikko A, Staerman F, Valdagni R, Pickles T, et al. Radical
prostatectomy for low-risk prostate cancer following initial active
surveillance: results from a prospective observational study. Eur Urol. 2012;
62(2):195–200.
10. Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D,
et al. Optimization of initial prostate biopsy in clinical practice: sampling,
labeling and specimen processing. J Urol. 2013;189(6):2039–46.
Aa et al. BMC Urology           (2019) 19:23 Page 8 of 9
11. Sedelaar JP, van Roermund JG, van Leenders GL, van de Kaa CA H, Wijkstra
H, de la Rosette JJ. Three-dimensional grayscale ultrasound: evaluation of
prostate cancer compared with benign prostatic hyperplasia. Urology. 2001;
57(5):914–20.
12. Mehta SS, Azzouzi AR, Hamdy FC. Three dimensional ultrasound and
prostate cancer. World J Urol. 2004 Nov;22(5):339–45.
13. Mitterberger M, Pinggera GM, Pallwein L, Gradl J, Frauscher F, Bartsch G, et
al. The value of three-dimensional transrectal ultrasonography in staging
prostate cancer. BJU Int. 2007 Jul;100(1):47–50.
14. Cool D, Sherebrin S, Izawa J, Chin J, Fenster A. Design and evaluation of a
3D transrectal ultrasound prostate biopsy system. Medical physics. 2008;
35(10):4695–707.
15. Cohen M, Cytron S, Nativ O, Shmitz A, Yudkevich B, Shental J. 816 3D TRUS
prostate biopsy recording and guidance - the Navigo system. Eur Urol
Suppl. 2012;11(1):e816,e816a.
16. Chin JL, Downey DB, Mulligan M, Fenster A. Three-dimensional transrectal
ultrasound guided cryoablation for localized prostate cancer in nonsurgical
candidates: a feasibility study and report of early results. J Urol. 1998;159(3):
910–4.
17. Peltier A, Aoun F, El-Khoury F, Hawaux E, Limani K, Narahari K, et al. 3D
versus 2D systematic Transrectal ultrasound-guided prostate biopsy:
higher Cancer detection rate in clinical practice. Prostate cancer. 2013;
2013:783243.
18. Pryaluhkin AE, Vandromme A, Dellmann A, Donhuijsen K, Hammerer PG.
Prostate biopsy core handling: comparison of contemporary preembedding
methods. Urol Int. 2015;95(2):203–8.
19. Rogatsch H, Mairinger T, Horninger W, Gschwendtner A, Bartsch G, Mikuz G.
Optimized preembedding method improves the histologic yield of prostate
core needle biopsies. Prostate. 2000;42(2):124–9.
20. Rogatsch H, Moser P, Volgger H, Horninger W, Bartsch G, Mikuz G, et al.
Diagnostic effect of an improved preembedding method of prostate needle
biopsy specimens. Hum Pathol. 2000;31(9):1102–7.
21. Cohen M, Shefler A, Patsiansky S, Shapira-Schweitzer K, Nativ O, Bejar J. The
SmartBx™ – initial experience with a semi-automated prostate biopsy core
download system. Poster presented at the 6th international symposium on
focal therapy and imaging in prostate and kidney Cancer, Amsterdam.
Poster retrieved from: https://www.focaltherapy.org/2013/Poster_Abstracts/
Focal_2013_PP-22a.pdf.
22. Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ. Positive
predictive value of prostate biopsy indicated by prostate-specific-antigen-
based prostate cancer screening: trends over time in a European
randomized trial*. BJU Int. 2012;110(11):1654–60.
23. Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction
of prostate cancer risk: the role of prostate volume and digital rectal
examination in the ERSPC risk calculators. Eur Urol. 2012;61(3):577–83.
https://doi.org/10.1016/j.eururo.2011.11.012
24. Lawrentschuk N, Toi A, Lockwood GA, Evans A, Finelli A, O’Malley M, et al.
Operator is an independent predictor of detecting prostate cancer at
transrectal ultrasound guided prostate biopsy. J Urol. 2009;182(6):2659–63.
25. Gayet M, van der Aa A, Schmitz P, Beerlage HP, Schrier BP, Mulders PF, et al.
3D Navigo™ versus TRUS-guided prostate biopsy in prostate cancer
detection. World J Urol. 2016;34(9):1255–60.
26. Cool DW, Connolly MJ, Sherebrin S, Eagleson R, Izawa JI, Amann J, et al.
Repeat prostate biopsy accuracy: simulator-based comparison of two- and
three dimensional transrectal USmodalities. Radiology. 2010;254(2):587–94.
27. Wan G, Wei Z, Gardi L, Downey DB, Fenster A. Brachytherapy needle
deflection evaluation and correction. Med Phys. 2005;32:902–9.
28. Iczkowski KA, Casella G, Seppala RJ, Jones GL, Mishler BA, Qian J, et al.
Needle core length in sextant biopsy influences prostate cancer detection
rate. Urology. 2002;59(5):698–703.
29. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al.
The 2014 International Society of Urological Pathology (ISUP) consensus
conference on Gleason grading of prostatic carcinoma: definition of
grading patterns and proposal for a new grading system. Am J Surg Pathol.
2016;40(2):244–52.
30. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA,
Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-Cancer
diagnosis. N Engl J Med. 2018;378(19):1767–77. https://doi.org/10.1056/
NEJMoa1801993
31. Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier
F. Use of prostate systematic and targeted biopsy on the basis of
multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective,
multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100–9.
32. van der Leest M, Cornel E, Israel B, Hendriks R, Padhani AR, Hoogenboom M,
et al. Head-to-head comparison of Transrectal ultrasound-guided prostate
biopsy versus multiparametric prostate resonance imaging with subsequent
magnetic resonance-guided biopsy in biopsy-naïve men with elevated
prostate-specific antigen: a large prospective multicenter clinical study. Eur
Urol. 2018; In Press.
33. Moldovan PC, van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den
Bergh RCN, et al. What is the negative predictive value of multiparametric
magnetic resonance imaging in excluding prostate Cancer at biopsy? A
systematic review and meta-analysis from the European Association of
Urology prostate Cancer guidelines panel. Eur Urol. 2017;72(2):250–66.
Aa et al. BMC Urology           (2019) 19:23 Page 9 of 9
